Literature DB >> 32998816

International consensus definitions of clinical trial outcomes for kidney failure: 2020.

Adeera Levin1, Rajiv Agarwal2, William G Herrington3, Hiddo L Heerspink4, Johannes F E Mann5, Shahnaz Shahinfar6, Katherine R Tuttle7, Jo-Ann Donner8, Vivekanand Jha9, Masaomi Nangaku10, Dick de Zeeuw4, Meg J Jardine11, Kenneth W Mahaffey12, Aliza M Thompson13, Mary Beaucage14, Kate Chong15, Glenda V Roberts16, Duane Sunwold17, Hans Vorster18, Madeleine Warren19, Sandrine Damster8, Charu Malik8, Vlado Perkovic20.   

Abstract

Kidney failure is an important outcome for patients, clinicians, researchers, healthcare systems, payers, and regulators. However, no harmonized international consensus definitions of kidney failure and key surrogates of progression to kidney failure exist specifically for clinical trials. The International Society of Nephrology convened an international multi-stakeholder meeting to develop consensus on this topic. A core group, experienced in design, conduct, and outcome adjudication of clinical trials, developed a database of 64 randomized trials and the 163 included definitions relevant to kidney failure. Using an iterative process, a set of proposed consensus definitions were developed and subsequently vetted by the larger multi-stakeholder group of 83 participants representing 18 different countries. The consensus of the meeting participants was that clinical trial kidney failure outcomes should be comprised of a composite that includes receipt of a kidney transplant, initiation of maintenance dialysis, and death from kidney failure; it may also include outcomes based solely on laboratory measurements of glomerular filtration rate: a sustained low glomerular filtration rate and a sustained percent decline in glomerular filtration rate. Discussion included important considerations, such as (i) recognition of existing nomenclature for kidney failure; (ii) applicability across resource settings; (iii) ease of understanding for all stakeholders; and (iv) avoidance of inappropriate complexity so that the definitions can be used across ranges of populations and trial methodologies. The final definitions reflect the consensus for use in clinical trials.
Copyright © 2020 International Society of Nephrology. All rights reserved.

Entities:  

Keywords:  continuous kidney replacement therapy; kidney failure; maintenance dialysis; transplantation

Mesh:

Year:  2020        PMID: 32998816     DOI: 10.1016/j.kint.2020.07.013

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  11 in total

1.  A Core Outcome Set for Trials in Glomerular Disease: A Report of the Standardized Outcomes in Nephrology-Glomerular Disease (SONG-GD) Stakeholder Workshops.

Authors:  Simon A Carter; Liz Lightstone; Dan Cattran; Allison Tong; Arvind Bagga; Sean J Barbour; Jonathan Barratt; John Boletis; Dawn J Caster; Rosanna Coppo; Fernando C Fervenza; Jürgen Floege; Michelle A Hladunewich; Jonathan J Hogan; A Richard Kitching; Richard A Lafayette; Ana Malvar; Jai Radhakrishnan; Brad H Rovin; Nicole Scholes-Robertson; Hernán Trimarchi; Hong Zhang; Samaya Anumudu; Yeoungjee Cho; Talia Gutman; Emma O'Lone; Andrea K Viecelli; Eric Au; Karolis Azukaitis; Amanda Baumgart; Amelie Bernier-Jean; Louese Dunn; Martin Howell; Angela Ju; Charlotte Logeman; Melissa Nataatmadja; Benedicte Sautenet; Ankit Sharma; Jonathan C Craig
Journal:  Clin J Am Soc Nephrol       Date:  2021-12-30       Impact factor: 8.237

2.  The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics.

Authors:  Muh Geot Wong; Jicheng Lv; Michelle A Hladunewich; Vivekanand Jha; Lai Seong Hooi; Helen Monaghan; Minghui Zhao; Sean Barbour; Heather N Reich; Daniel Cattran; Richard Glassock; Adeera Levin; Meg J Jardine; David C Wheeler; Mark Woodward; Laurent Billot; Tak Mao Chan; Zhi-Hong Liu; David W Johnson; Alan Cass; John Feehally; Jürgen Floege; Giuseppe Remuzzi; Yangfeng Wu; Rajiv Agarwal; Hong Zhang; Vlado Perkovic
Journal:  Am J Nephrol       Date:  2021-11-03       Impact factor: 3.754

3.  Effect of Low-Dose Methotrexate on eGFR and Kidney Adverse Events: A Randomized Clinical Trial.

Authors:  Jeffrey A Sparks; Kathleen M M Vanni; Matthew A Sparks; Chang Xu; Leah M Santacroce; Robert J Glynn; Paul M Ridker; Daniel H Solomon
Journal:  J Am Soc Nephrol       Date:  2021-09-22       Impact factor: 10.121

Review 4.  Diabetes: how to manage chronic kidney disease.

Authors:  Jennifer N Clements
Journal:  Drugs Context       Date:  2022-06-14

5.  Importance of standardizing renal outcomes in clinical trials: illustration by recent sodium glucose cotransporter 2 inhibitor studies.

Authors:  Daniël H van Raalte; Petter Bjornstad; Hiddo J L Heerspink; Frederik Persson; David Z I Cherney
Journal:  Kidney Int       Date:  2021-03       Impact factor: 10.612

6.  Randomized clinical study to evaluate the effect of personalized therapy on patients with immunoglobulin A nephropathy.

Authors:  Francesco P Schena; Giovanni Tripepi; Michele Rossini; Daniela I Abbrescia; Carlo Manno
Journal:  Clin Kidney J       Date:  2021-12-15

7.  Potential Surrogate Outcomes for Kidney Failure in Advanced CKD: Evaluation of Power and Predictive Ability in CKDopps.

Authors:  Jarcy Zee; Daniel Muenz; Keith P McCullough; Brian Bieber; Marie Metzger; Natalia Alencar de Pinho; Antonio A Lopes; Danilo Fliser; Bruce M Robinson; Eric Young; Ronald L Pisoni; Bénédicte Stengel; Roberto Pecoits-Filho
Journal:  Kidney Med       Date:  2021-12-11

8.  Clonal Hematopoiesis of Indeterminate Potential and Diabetic Kidney Disease: A Nested Case-Control Study.

Authors:  Sara Denicolò; Verena Vogi; Felix Keller; Stefanie Thöni; Susanne Eder; Hiddo J L Heerspink; László Rosivall; Andrzej Wiecek; Patrick B Mark; Paul Perco; Johannes Leierer; Andreas Kronbichler; Marion Steger; Simon Schwendinger; Johannes Zschocke; Gert Mayer; Emina Jukic
Journal:  Kidney Int Rep       Date:  2022-02-03

9.  Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial.

Authors: 
Journal:  Nephrol Dial Transplant       Date:  2022-06-23       Impact factor: 7.186

10.  A systematic review of statistical methodology used to evaluate progression of chronic kidney disease using electronic healthcare records.

Authors:  Faye Cleary; David Prieto-Merino; Dorothea Nitsch
Journal:  PLoS One       Date:  2022-07-29       Impact factor: 3.752

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.